Stock Track | Viridian Therapeutics Soars 5.67% on Analyst Rating Reiteration

Stock Track12-18

Shares of Viridian Therapeutics, Inc. (VRDN) surged 5.67% in Tuesday's intraday trading session, following an analyst rating reiteration from RBC Capital.

RBC Capital maintained its "Outperform" rating on Viridian Therapeutics, likely reflecting continued confidence in the company's prospects and growth potential. While the specific details of the analyst report are not available, rating reiterations from respected research firms can often provide a boost to a company's stock price.

The stock's significant gain on Tuesday highlights the market's positive reaction to the analyst rating reiteration, which may have reinforced investor sentiment and encouraged buying activity in Viridian Therapeutics' shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131709534?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 10:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131709534","market":"us","top_or_hot":-1,"title":"Stock Track | Viridian Therapeutics Soars 5.67% on Analyst Rating Reiteration","media":"Stock Track","content":"<p>Shares of Viridian Therapeutics, Inc. (VRDN) surged 5.67% in Tuesday's intraday trading session, following an analyst rating reiteration from RBC Capital.</p>\n\n<p>RBC Capital maintained its \"Outperform\" rating on Viridian Therapeutics, likely reflecting continued confidence in the company's prospects and growth potential. While the specific details of the analyst report are not available, rating reiterations from respected research firms can often provide a boost to a company's stock price.</p>\n\n<p>The stock's significant gain on Tuesday highlights the market's positive reaction to the analyst rating reiteration, which may have reinforced investor sentiment and encouraged buying activity in Viridian Therapeutics' shares.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Viridian Therapeutics Soars 5.67% on Analyst Rating Reiteration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Viridian Therapeutics Soars 5.67% on Analyst Rating Reiteration\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-18 10:34 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Viridian Therapeutics, Inc. (VRDN) surged 5.67% in Tuesday's intraday trading session, following an analyst rating reiteration from RBC Capital.\nRBC Capital maintained its \"Outperform\" ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRDN","symbol_name":"Viridian Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1131709534","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131709534","pubTimestamp":1734489264,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Viridian Therapeutics, Inc.  surged 5.67% in Tuesday's intraday trading session, following an analyst rating reiteration from RBC Capital.RBC Capital maintained its \"Outperform\" rating on Viridian Therapeutics, likely reflecting continued confidence in the company's prospects and growth potential. While the specific details of the analyst report are not available, rating reiterations from respected research firms can often provide a boost to a company's stock price.The stock's signific","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRDN":"Viridian Therapeutics, Inc."},"translate_title":"分析师重申评级，Viridian Therapeutics股价飙升5.67%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRDN":1},"content_text":"Shares of Viridian Therapeutics, Inc. (VRDN) surged 5.67% in Tuesday's intraday trading session, following an analyst rating reiteration from RBC Capital.\nRBC Capital maintained its \"Outperform\" rating on Viridian Therapeutics, likely reflecting continued confidence in the company's prospects and growth potential. While the specific details of the analyst report are not available, rating reiterations from respected research firms can often provide a boost to a company's stock price.\nThe stock's significant gain on Tuesday highlights the market's positive reaction to the analyst rating reiteration, which may have reinforced investor sentiment and encouraged buying activity in Viridian Therapeutics' shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131709534"}